---
title: Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
date: '2024-04-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38687605/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240501181344&v=2.18.0.post9+e462414
source: Blood
description: Mutations in UBA1, which are disease-defining for VEXAS syndrome, have
  been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here,
  we define the prevalence and clinical associations of UBA1 mutations in a representative
  cohort of patients with MDS. Digital droplet PCR profiling of a selected cohort
  of 375 male patients lacking MDS disease-defining mutations or established WHO disease
  classification identified 28 patients (7%) with UBA1 p.M41T/V/L mutations. Using
  ...
disable_comments: true
---
Mutations in UBA1, which are disease-defining for VEXAS syndrome, have been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here, we define the prevalence and clinical associations of UBA1 mutations in a representative cohort of patients with MDS. Digital droplet PCR profiling of a selected cohort of 375 male patients lacking MDS disease-defining mutations or established WHO disease classification identified 28 patients (7%) with UBA1 p.M41T/V/L mutations. Using ...